Press Releases Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Real-time Estimate Cboe BZX Other stock markets 01:59:00 2024-05-22 pm EDT			5-day change	1st Jan Change
16.1 ^USD	+2.58%		+10.77%	+6.36%

May. 20	Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing	MT
May. 16	Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	May. 16	GL
Entrada Therapeutics : Corporate Presentation	May. 07	PU
Entrada Therapeutics Reports First Quarter 2024 Financial Results	May. 07	GL
Entrada Therapeutics : Corporate Presentation	Mar. 13	PU
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 13	GL
Entrada Therapeutics : Corporate Presentation	Mar. 04	PU
Entrada Therapeutics to Present at Upcoming Investor Conferences	Feb. 07	GL
Entrada Therapeutics Promotes Nathan J. Dowden to President	Jan. 03	GL
Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA	Dec. 18	PR
Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA	Nov. 29	PR
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy	Nov. 22	GL
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy	Nov. 22	AQ
Entrada Therapeutics Reports Third Quarter 2023 Financial Results	Nov. 07	GL
Entrada Therapeutics to Present at Upcoming Investor Conferences	23-10-12	GL
Entrada Therapeutics to Present at Upcoming Investor Conferences	23-10-12	AQ
Entrada Therapeutics : Corporate Presentation	23-09-21	PU
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy	23-09-21	GL
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy	23-09-21	AQ
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community	23-09-07	GL
Entrada Therapeutics : Corporate Presentation	23-09-01	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Press Releases

Filters